Hims & Hers Health (NYSE:HIMS) Shares Up 1.1% - What's Next?

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) shot up 1.1% on Thursday . The stock traded as high as $59.90 and last traded at $58.20. Approximately 14,727,372 shares changed hands during trading, a decline of 30% from the average daily volume of 20,937,689 shares. The stock had previously closed at $57.56.

Analysts Set New Price Targets

HIMS has been the topic of a number of research analyst reports. UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Leerink Partners upped their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and a consensus target price of $38.00.

Hims & Hers Health Price Performance

The stock's 50 day moving average is $44.50 and its two-hundred day moving average is $37.98. The stock has a market capitalization of $12.38 billion, a PE ratio of 125.85 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue was up 110.7% on a year-over-year basis. During the same period last year, the business earned $0.05 EPS. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 23,287 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the transaction, the insider now owns 209,661 shares in the company, valued at $7,193,468.91. This represents a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 5,600 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $57.00, for a total value of $319,200.00. Following the completion of the sale, the insider now directly owns 256,380 shares of the company's stock, valued at $14,613,660. The trade was a 2.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 628,067 shares of company stock worth $25,832,688. 13.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of the company. Farallon Capital Management LLC raised its position in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the period. Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after buying an additional 2,020,722 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Hims & Hers Health during the first quarter worth about $58,403,000. Finally, Yong Rong HK Asset Management Ltd acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth about $41,104,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.